Hochschulschrift
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
VIII, 237 Seiten
- Sprache
-
Englisch
- Anmerkungen
-
Illustrationen
Enthält Sonderabdrucke
Albert-Ludwigs-Universität Freiburg im Breisgau, Dissertation, 2016
- Klassifikation
-
Medizin, Gesundheit
Biowissenschaften, Biologie
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Entstanden
- Februar 2016
Ähnliche Objekte (12)
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Treatment-free remission in chronic myeloid leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Myeloid cells and therapy resistance in chronic lymphocytic leukemia
Myeloid cells and therapy resistance in Chronic Lymphocytic Leukemia
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Treatment-free remission in chronic myeloid leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Myeloid cells and therapy resistance in chronic lymphocytic leukemia
Myeloid cells and therapy resistance in Chronic Lymphocytic Leukemia
Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Treatment-free remission in chronic myeloid leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Myeloid cells and therapy resistance in chronic lymphocytic leukemia